CoChat

Single-cell spatial analysis with Xenium reveals anti-tumour responses of CXCL13 + T and CXCL9+ cells after radiotherapy combined with anti-PD-L1 therapy

Open access

The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index, and 1 are not checked yet.

Abstract

Background: The standard treatment for unresectable non-small cell lung cancer (NSCLC) is anti-PD-L1 therapy combined with chemoradiotherapy (anti-PD-L1-CRT). Although some patients achieve complete cancer eradication and cure, more than half of patients retain persistent cancer cells. Our research aimed to unravel the nuanced mechanisms involved in both immune attack and evasion induced by anti-PD-L1-CRT with single cell spatial transcriptome. Methods: Xenium is a cutting-edge single-cell spatial analysis tool that enables pathology-based and single-cell analyses while preserving spatial information. In our study, we used Xenium to identify the tumour microenvironment (TME), immune dynamics, and residual cancer cells at the single-cell level following treatment with anti-PD-L1-CRT. Results: Posttreatment alterations included a significant increase in CXCL9+ cells and CXCL13 + T cells, particularly around tumour cells. Additionally, we discovered that CXCL13 + T cells directly impact cancer cells in the posttreatment environment. Moreover, we identified clusters of immune-cold cancer cells posttreatment, revealing their activation of DNA repair pathways and high proliferative capacity. The novel spatial analysis tool Xenium enabled identification of the immune environment at the single-cell level following treatment with anti-PD-L1-CRT, elucidating its characteristics. Conclusions: These findings suggest potential advancements in developing new treatments to improve posttreatment immune responses and address resistance challenges.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41416-025-03088-0

Cites

55 of 56 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Evaluation of tissues and Xenium analysis after treatment with anti-PD-L1 combined with chemoradiotherapy. a Characteristics of the tissue samples used in this study. The cell number indicates the number of cells that can be analysed with Xenium. Posttreatment histology revealed stable disease (SD), major pathological response (MPR), and complete response (CR). b Representative HE staining image of pre- and posttreatment tumours. Cancer cells were delineated via HE staining (yellow line). c, d Representative images of HE staining, cell clustering and gene expression. After each cell line was distinguished and utilizing 302 gene expression patterns, pretreatment cells were categorized into 11 clusters, and posttreatment cells were classified into 22 clusters. Each cluster was classified as epithelial (KRT5 + , CDH1 + ), CAF (COL1A1 + ), myeloid (CD68 + , CD163 + ), LYM (lymphocyte, CD3E + , CD4 + , CD8 + ), plasma (POU2AF1 + ), or U.C. (dead cells or unclassified cells).
Fig. 1 Evaluation of tissues and Xenium analysis after treatment with anti-PD-L1 combined with chemoradiotherapy. a Characteristics of the tissue samples used in this study. The cell number indicates the number of cells that can be analysed with Xenium. Posttreatment histology revealed stable disease (SD), major pathological response (MPR), and complete response (CR). b Representative HE staining image of pre- and posttreatment tumours. Cancer cells were delineated via HE staining (yellow line). c, d Representative images of HE staining, cell clustering and gene expression. After each cell line was distinguished and utilizing 302 gene expression patterns, pretreatment cells were categorized into 11 clusters, and posttreatment cells were classified into 22 clusters. Each cluster was classified as epithelial (KRT5 + , CDH1 + ), CAF (COL1A1 + ), myeloid (CD68 + , CD163 + ), LYM (lymphocyte, CD3E + , CD4 + , CD8 + ), plasma (POU2AF1 + ), or U.C. (dead cells or unclassified cells).CC BY · PubMed Central
Fig. 2 Characterization of gene expression profiles of cells in tissue samples obtained following combined treatment with anti-PD-L1 antibodies and chemoradiotherapy. a Workflow of the analysis in this study. b, c The number of cells in the total field analysed before (Patients 1, 2, and 7) and after (Patients 1, 3, 7 and 8) surgery. Positivity was defined as ≥2 or above. In all pre-post comparisons, a statistically significant difference was observed (P < 0.05, Student’s t-test). d The number of white blood cells (WBCs) and lymphocytes in the plasma. Pre: plasma within 2 weeks before treatment; Post: plasma within 2 weeks after resection. e Bar plot illustrating differences in the density of mRNA expression per cell area between pretreatment (Patient 1: 1029 cells, Patient 3: 1248 cells, and Patient 7: 340 cells) and posttreatment (Patient 1: 1502 cells, Patient 2: 1059 cells, and Patient 7: 1049). The x-axis indicates the effect size (Cohen’s d), and the y-axis indicates each gene with significant changes in expression (Welch’s t test, P < 0.05). f Confirmation of gene expression through Xenium Explorer. g Heatmap with dendrogram illustrating differences in the density of gene expression between manually delineated intertumoural, ≤20 μm, ≤70 μm, and ≤120 μm regions. The x-axis indicates each delineated region, and the y-axis indicates 302 genes in the Xenium I lung panel. h Merged images of gene expression and HE staining.
Fig. 2 Characterization of gene expression profiles of cells in tissue samples obtained following combined treatment with anti-PD-L1 antibodies and chemoradiotherapy. a Workflow of the analysis in this study. b, c The number of cells in the total field analysed before (Patients 1, 2, and 7) and after (Patients 1, 3, 7 and 8) surgery. Positivity was defined as ≥2 or above. In all pre-post comparisons, a statistically significant difference was observed (P < 0.05, Student’s t-test). d The number of white blood cells (WBCs) and lymphocytes in the plasma. Pre: plasma within 2 weeks before treatment; Post: plasma within 2 weeks after resection. e Bar plot illustrating differences in the density of mRNA expression per cell area between pretreatment (Patient 1: 1029 cells, Patient 3: 1248 cells, and Patient 7: 340 cells) and posttreatment (Patient 1: 1502 cells, Patient 2: 1059 cells, and Patient 7: 1049). The x-axis indicates the effect size (Cohen’s d), and the y-axis indicates each gene with significant changes in expression (Welch’s t test, P < 0.05). f Confirmation of gene expression through Xenium Explorer. g Heatmap with dendrogram illustrating differences in the density of gene expression between manually delineated intertumoural, ≤20 μm, ≤70 μm, and ≤120 μm regions. The x-axis indicates each delineated region, and the y-axis indicates 302 genes in the Xenium I lung panel. h Merged images of gene expression and HE staining.CC BY · PubMed Central
Fig. 3 Single-cell spatial transcriptome analysis revealed characteristics of CXCL9+ and CXCL13+ cells that accumulated among cancer cells after anti-PD-L1 combination therapy. a Treatment, tissue, genotype, response, and number of cells expressing CXCL9, CXCL13, CD274, CTLA4, ICOS, IDO1, LAG3, CXCL5, and CXCL14. b Peripheral tumour gene expression of CXCL13 and CXCL9 in Patient 7. Posts 1-4 show residual cancer cells, and post 5 shows only accumulated lymphocytes. c CXCL13 and CXCL9 expression in Patient 7 pre, Patient 8 post, and Patient 11 posttissue. d Bubble chart with a colour scale showing the expression level and proportion of cell marker genes and ICI target genes in CXCL13+ and CXCL9+ cells using in situ Xenium data for Patient 7. The x-axis indicates the cells, the y-axis indicates each marker gene, the colour scale indicates the z score of the mean number of positive cells for each marker gene, and the circle size indicates the proportion of positive cells for each marker gene. e CXCL13 + CD8 + T cells coexpressing exhaustion marker genes on tumour cells. f CD8 + T cells coexpressing exhaustion marker genes on tumour cells. f CD68− and CD163+ myeloid cells coexpressing CXCL9.
Fig. 3 Single-cell spatial transcriptome analysis revealed characteristics of CXCL9+ and CXCL13+ cells that accumulated among cancer cells after anti-PD-L1 combination therapy. a Treatment, tissue, genotype, response, and number of cells expressing CXCL9, CXCL13, CD274, CTLA4, ICOS, IDO1, LAG3, CXCL5, and CXCL14. b Peripheral tumour gene expression of CXCL13 and CXCL9 in Patient 7. Posts 1-4 show residual cancer cells, and post 5 shows only accumulated lymphocytes. c CXCL13 and CXCL9 expression in Patient 7 pre, Patient 8 post, and Patient 11 posttissue. d Bubble chart with a colour scale showing the expression level and proportion of cell marker genes and ICI target genes in CXCL13+ and CXCL9+ cells using in situ Xenium data for Patient 7. The x-axis indicates the cells, the y-axis indicates each marker gene, the colour scale indicates the z score of the mean number of positive cells for each marker gene, and the circle size indicates the proportion of positive cells for each marker gene. e CXCL13 + CD8 + T cells coexpressing exhaustion marker genes on tumour cells. f CD8 + T cells coexpressing exhaustion marker genes on tumour cells. f CD68− and CD163+ myeloid cells coexpressing CXCL9.CC BY · PubMed Central
Fig. 4 CXCL13 + CD8 + T cells accumulate in posttreatment cancer tissue and directly act on cancer cells. a Localization of CXCL13 − CD8 + T cells and CXCL13 + CD8 + T cells in Patient 7. The regions enclosed by the yellow rectangle in the upper row are shown in the lower row. The green dashed lines are the tumour surface, and the yellow dashed lines are the contour lines at 30 µm intervals. b Image shows the tumour surfaces (green) and contours (red) at 30 µm intervals (−60 to 150 μm) in two areas in Patient 7. c Bar plot shows the proportions of CXCL13 + CD8 + T cells and CXCL13 − CD8 + T cells in each region. d CXCL13 + CD8 + T cells expressing GZMB were near or inside the tumour in Patients 1, 2, and 7.
Fig. 4 CXCL13 + CD8 + T cells accumulate in posttreatment cancer tissue and directly act on cancer cells. a Localization of CXCL13 − CD8 + T cells and CXCL13 + CD8 + T cells in Patient 7. The regions enclosed by the yellow rectangle in the upper row are shown in the lower row. The green dashed lines are the tumour surface, and the yellow dashed lines are the contour lines at 30 µm intervals. b Image shows the tumour surfaces (green) and contours (red) at 30 µm intervals (−60 to 150 μm) in two areas in Patient 7. c Bar plot shows the proportions of CXCL13 + CD8 + T cells and CXCL13 − CD8 + T cells in each region. d CXCL13 + CD8 + T cells expressing GZMB were near or inside the tumour in Patients 1, 2, and 7.CC BY · PubMed Central
Fig. 5 CXCL13 + CD8 + T cells accumulate via the CXCL16– CXCR6 axis and trigger the IFNG pathway. a Bubble chart with a colour scale showing the average expression level and proportion of genes associated with receptors in CXCL13 − CD8 + , CXCL13 + CD8 + , CXCL9 − CD68 + , CXCL9 + CD68+ and CXCL9 − CD68+ cells according to gene expression data for Patient 7. The x-axis indicates the cell type, the y-axis indicates the marker gene, the colour scale indicates the z score of the mean number of positive cells for each marker gene, and the circle size indicates the proportion of positive cells for each marker gene for each type of cell. b, c Bubble chart of genes associated with humoral immunity and regulators in CXCL13 − CD8 + , CXCL13 + CD8 + , CXCL9- CD68 + , CXCL9 + CD68 + , CXCL9 − CD68 + , CD274 − EPCAM + , and CD274 + EPCAM+ cells. d CXCL13 + CD8 + T cells coexpress IFNG, and CXCL9 and CXCL10 expression is found near these cells. e Heatmaps indicating spatial enrichment of the IFN-mediated signalling pathway (log-adjusted P value) and expression levels of CXCL13, CXCL9, and CXCL10 (normalized count). The values below the heatmaps are the Pearson correlation coefficients between expression levels and enrichment of IFN-mediated signalling pathways. f Models of cell‒cell interactions in the tumour environment.
Fig. 5 CXCL13 + CD8 + T cells accumulate via the CXCL16– CXCR6 axis and trigger the IFNG pathway. a Bubble chart with a colour scale showing the average expression level and proportion of genes associated with receptors in CXCL13 − CD8 + , CXCL13 + CD8 + , CXCL9 − CD68 + , CXCL9 + CD68+ and CXCL9 − CD68+ cells according to gene expression data for Patient 7. The x-axis indicates the cell type, the y-axis indicates the marker gene, the colour scale indicates the z score of the mean number of positive cells for each marker gene, and the circle size indicates the proportion of positive cells for each marker gene for each type of cell. b, c Bubble chart of genes associated with humoral immunity and regulators in CXCL13 − CD8 + , CXCL13 + CD8 + , CXCL9- CD68 + , CXCL9 + CD68 + , CXCL9 − CD68 + , CD274 − EPCAM + , and CD274 + EPCAM+ cells. d CXCL13 + CD8 + T cells coexpress IFNG, and CXCL9 and CXCL10 expression is found near these cells. e Heatmaps indicating spatial enrichment of the IFN-mediated signalling pathway (log-adjusted P value) and expression levels of CXCL13, CXCL9, and CXCL10 (normalized count). The values below the heatmaps are the Pearson correlation coefficients between expression levels and enrichment of IFN-mediated signalling pathways. f Models of cell‒cell interactions in the tumour environment.CC BY · PubMed Central
Fig. 6 Characterization of immunologically hot and cold cancer cells after anti-PD-L1 combined with chemoradiotherapy. a Image of HE staining of mixed hot and cold tumours. b, c Violin plot of genes whose expression significantly differed (p < 0.05; Welch’s t test) between hot and cold tumours in Patient 7. The y-axis shows the density of gene expression per cell area (μm2). Genes are shown separately based on their categorization as hot, cold, or ICI-targetable genes. d Confirmation of gene expression through Xenium Explorer.
Fig. 6 Characterization of immunologically hot and cold cancer cells after anti-PD-L1 combined with chemoradiotherapy. a Image of HE staining of mixed hot and cold tumours. b, c Violin plot of genes whose expression significantly differed (p < 0.05; Welch’s t test) between hot and cold tumours in Patient 7. The y-axis shows the density of gene expression per cell area (μm2). Genes are shown separately based on their categorization as hot, cold, or ICI-targetable genes. d Confirmation of gene expression through Xenium Explorer.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 56 references

Cited by

See all 16

Metadata

Authors
Sakai, S. A., Oyoshi, H., Nakamura, M., Taki, T., Nomura, K., Hojo, H., Hirata, H., Motegi, A., Nakamura, Y., Zenkoh, J., Aokage, K., Hamada, A., Kojima, M., Kuwata, T., Tsuchihara, K., Akimoto, T., Soh, J., Mitsudomi, T., Tsuboi, M., Ishii, G., Suzuki, Y., Suzuki, A., Yamashita, R., & Kageyama, S.-I.
Affiliations
  • National Cancer Center Exploratory Oncology Research & Clinical Trial Center (JP)
  • National Cancer Center Hospital East (JP)
  • The University of Tokyo (JP)
  • Kindai University (JP)
  • Kyoto Prefectural University of Medicine (JP)
Corresponding author
  • Suzuki, Ayako
  • Yamashita, Riu
  • Kageyama, Shun-Ichiro
Venue
British Journal of Cancer
Published
2025-07-16
Volume
133
Issue
6
Pages
795-808
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W4412481978
Cited by
15
References
55
Citations by year
2026: 12 · 2025: 3
FWCI
6.21
Type
journal article
Language
en
Open access
Licence
Locations
  • British Journal of Cancer (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
Funders
  • Ministry of Education, Culture, Sports, Science and Technology (21K07582)
  • MEXT | Japan Science and Technology Agency (JPMJSP2108)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Single-cell and spatial transcriptomics
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
non-small cell lung cancer, PD-L1 blockade, chemoradiotherapy, tumor microenvironment, single-cell spatial transcriptomics, Xenium, residual tumor cells, immune evasion, DNA repair pathways, tumor cell proliferation, antitumor immunity
MeSH terms
Immune Checkpoint Inhibitors, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, T-Lymphocytes, Cell Line, Tumor, Chemokine CXCL9, Chemokine CXCL13, Single-Cell Analysis, Tumor Microenvironment, Chemoradiotherapy, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Single-cell spatial analysis with Xenium reveals anti-tumour responses of CXCL13 + T and CXCL9+ cells after radiotherapy combined with anti-PD-L1 therapy. https://app.cochat.ai/papers/10.1038/s41416-025-03088-0
The paper
Sakai, S. A., Oyoshi, H., Nakamura, M., Taki, T., Nomura, K., Hojo, H., Hirata, H., Motegi, A., Nakamura, Y., Zenkoh, J., Aokage, K., Hamada, A., Kojima, M., Kuwata, T., Tsuchihara, K., Akimoto, T., Soh, J., Mitsudomi, T., Tsuboi, M., . . . Kageyama, S.-I. (2025). Single-cell spatial analysis with Xenium reveals anti-tumour responses of CXCL13 + T and CXCL9+ cells after radiotherapy combined with anti-PD-L1 therapy. British Journal of Cancer. https://doi.org/10.1038/s41416-025-03088-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.